Get the Stockscreener App
0.3505
14.37%
-0.0588
After Hours:
.36
0.0095
+2.71%
Hcw Biologics Inc stock is traded at $0.3505, with a volume of 629.15K.
It is down -14.37% in the last 24 hours and up +21.96% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$0.4093
Open:
$0.4
24h Volume:
629.15K
Relative Volume:
0.08
Market Cap:
$2.36M
Revenue:
$54,200
Net Income/Loss:
$-22.30M
P/E Ratio:
-0.0297
EPS:
-11.793
Net Cash Flow:
$-13.39M
1W Performance:
-13.99%
1M Performance:
+21.96%
6M Performance:
-89.44%
1Y Performance:
-94.75%
1-Day Range:
$0.315
$0.405
1-Week Range:
$0.315
$0.505
52-Week Range:
$0.25
$17.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.3505 | 2.76M | 54,200 | -22.30M | -13.39M | -11.79 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics Adjourns Meeting, Seeks Approval for Warrants - TipRanks
HCW Biologics adjourns stockholder meeting due to lack of quorum - Investing.com
HCW Biologics adjourns stockholder meeting due to lack of quorum By Investing.com - Investing.com UK
HCW Biologics Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - Quiver Quantitative
HCW Biologics (NASDAQ: HCWB) adjourns special meeting, shifts Armistice warrant votes - Stock Titan
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewswire
HCW Biologics Prepares Investor Outreach Tied to Public Offering - TipRanks
HCW Biologics (HCWB) ties $3M in consulting fees to S-1 offering - Stock Titan
[EFFECT] HCW Biologics Inc. SEC Filing - Stock Titan
HCW Biologics (NASDAQ: HCWB) seeks reverse split and warrant votes to support Nasdaq listing - Stock Titan
[ARS] HCW Biologics Inc. SEC Filing - Stock Titan
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCW Biologics (HCWB) Stock: Pancreatic Cancer Candidate Shows Early Preclinical Promise - parameter.io
HCW Biologics to file IND for HCW11-018b in first half of 2027 - TipRanks
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - Investing News Network
HCW Biologics delivers a major update for its T-cell engager program revealing mechanism of action - marketscreener.com
HCW Biologics plans 2027 IND filing for pancreatic cancer drug By Investing.com - Investing.com Australia
HCW Biologics plans 2027 IND filing for pancreatic cancer drug - Investing.com
HCW Biologics (NASDAQ: HCWB) targets $5.6M primary share and pre-funded warrant offering - Stock Titan
HCW Biologics (NASDAQ: HCWB) sets $5.6M stock and pre-funded warrant offer - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow | Hcw Biologics Inc. - Stock Titan
HCW Biologics (HCWB) Stock Sector Update (Investors Pile In) 2026-04-18Small Cap Breakout - Cổng thông tin điện tử Tỉnh Sơn La
HCW Biologics (HCWB) asks shareholders to approve reverse split, warrant repricing - Stock Titan
HCW Biologics Inc. Announces Amendment to Bylaws in SEC Form 8-K Filing April 2026 - Minichart
HCW Biologics Lowers Shareholder Meeting Quorum Requirement - TipRanks
Lower quorum rule adopted by HCW Biologics (NASDAQ: HCWB) - Stock Titan
HCWB SEC FilingsHcw Biologics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
HCWB Q4 2025 Earnings: HCW Biologics Inc. posts wide EPS miss with no revenueShared Buy Zones - Newser
EV Market: What is HCW Biologics Incs revenue forecast2026 Performance Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Trading Recap: Can HCW Biologics Inc stock double in the next yearDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Is HCW Biologics (HCWB) Stock Breaking Resistance | Price at $0.28, Up 3.77%Popular Market Picks - Newser
What should investors watch in HCW Biologics (HCWB) Stock | Price at $0.37, Up 8.31%Professional Trade Ideas - Newser
Growth Recap: Will HCW Biologics Inc outperform tech stocksEarnings Risk Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is HCW Biologics (HCWB) Stock Ready to Rally | Price at $0.27, Down 10.67%Crowd Sentiment Stocks - Newser
HCWB Stock Analysis: HCW Biologics Inc. Drops 16.67% to Key $0.3 Biotech Support - Xã Vĩnh Công
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Q4 revenue drops sharply on license suspension - TradingView
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
HCW Biologics (NASDAQ: HCWB) outlines immunotherapy pipeline, deals and IP - Stock Titan
HCW Biologics (NASDAQ: HCWB) 2025 loss, going concern and Nasdaq risk - Stock Titan
Hair-loss trial starts as HCW Biologics warns on funding runway - Stock Titan
Growth Value: Is HCW Biologics Inc gaining market shareDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
HCWB Should I Buy - Intellectia AI
Is HCW Biologics (HCWB) Stock trading below intrinsic value | Price at $0.34, Down 6.82%Earnings Miss Stocks - Cổng thông tin điện tử Tỉnh Sơn La
HCWB (HCW Biologics) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
HCWB Technical Analysis & Stock Price Forecast - Intellectia AI
Forecast Cut: Will HCW Biologics Inc benefit from green energy policiesWeekly Stock Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Dailyhunt
If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):